Need for a trial of solanezumab in mild Alzheimer’s disease

McCartney is right to be cautious about the effectiveness of solanezumab in Alzheimer’s disease, which she says might be a chance finding.1 But this is not because of the relatively small size of the trial but the nature of testing subgroups within an overall …